Previous 10 | Next 10 |
Conference being held Oct. 12th to 14th, 2021 in Carlsbad Athersys, Inc. (NASDAQ: ATHX) announced today that Dr. Robert W. Mays and Mr. William (B.J.) Lehmann will participate in person at the annual Cell & Gene Meeting on the Mesa Hybrid Conference to be held Octobe...
Positive ARDS Results in Japan should lead to approval and revenues. Enrollment complete in 220 patient stroke study in Japan. Japan's progressive regenerative medicine approval regulations bode well for success. Athersys shares have not reflected the upside of recent developm...
Palm Beach, FL –August 13, 2021 – FinancialNewsMedia.com News Commentary – The normal aging process is characterized by a progression of physiologic events that occur throughout the life cycle. Changes associated with aging occur throughout the body and are ...
Off-the-shelf stem cell therapy has potential to enhance recovery for stroke patients Athersys, Inc. (NASDAQ: ATHX) announced today that its partner, HEALIOS K.K. (“Healios”), has completed enrollment in its TREASURE study in Japan, evaluating MultiStem &...
Image source: The Motley Fool. Athersys (NASDAQ: ATHX) Q2 2021 Earnings Call Aug 09, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Athersys (ATHX) Q2 2021 Earnings Call Transcript
Athersys, Inc. (ATHX) Q2 2021 Earnings Conference Call August 09, 2021, 16:30 ET Company Participants Karen Hunady - Director, Corporate Communications & IR William Lehmann - President, COO, Secretary & Interim CEO Ivor Macleod - CFO & Principal Accounting Officer Conference Call ...
Announced promising topline ARDS results reported by Athersys partner, HEALIOS K.K., from its ONE-BRIDGE study Advanced partnership with Healios to enhance commercial readiness preparations for MultiStem in Japan Made continued progress in establishin...
Sphere 3D Corp (NASDAQ:ANY) +43% agreement to acquire exclusive rights for assignment of cryptocurrency mining assets Kaixin Auto (NASDAQ:KXIN) +23% on foraying into new energy vehicle business Switch (NYSE:SWCH) +19% on Q2 earnings Westport Fuel (NASDAQ:WPRT) +1...
Athersys (NASDAQ:ATHX) has added ~14.3% in the pre-market after the company announced that its partner in Japan, HEALIOS K.K. reported positive topline data for MultiStem cell therapy (invimestrocel) undergoing a study in patients with acute respiratory distress syndrome (ARDS). The open...
Athersys to continue to provide close support to Healios to advance its ARDS program Athersys, Inc. (NASDAQ: ATHX) announced today that its partner in Japan, HEALIOS K.K. (Healios), has released positive topline data from its ONE-BRIDGE clinical trial evaluating the safe...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...